Carlos Ortiz-Hidalgo
Carlos Ortiz-Hidalgo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Sergio Pina-Oviedo
Duke University Medical Center
2 shared publications - Adrian Alejandro Carballo-Zarate
Department of Pathology, Hospital Español, Mexico City 11520, Mexico
1 shared publication - Alejandra Zarate-Osorno
Department of Pathology, Hospital Español, Mexico City 11520, Mexico
1 shared publication - Alicia Rodríguez-Velasco
Servicio de Patología, Unidad Médica de Alta Especialidad, Hospital de Pediatría Silvestre Frenk Freund, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico
1 shared publication Angélica Rivas Hernández
1 shared publicationAranza Odeth Canchola-Ibarra
Departamento de Anatomía Patológica, Fundación Clínica Médica Sur, Ciudad de México, México
1 shared publication
Latest Publications
- 17 December 2025
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (4) , 841-852
Pathological and Immunohistochemical Features of Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomy Oblastic Differentiation (Malignant Triton Tumor) in the Context of the Malignant Peripheral Nerve Sheath Tumor Spectrum
Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas arising from Schwann cells or neurofibromas, comprising ∼10% of soft tissue sarcomas. Found in 8% to 13% of neurofibromatosis type 1 patients, they typically show spindle cells expressing S100 and SOX10. Some display heterologous differentiation (bone, cartilage, vessels, or glands). When rhabdomyosarcomatous features are present, they are called malignant peripheral nerve heath tumor with heterologous rhabdomyoblastic differentiation (malignant triton tumors), which are more prone to recurrence, metastasis, and worse outcomes. Epithelial differentiation does not affect prognosis. Despite advances in understanding MPNST biology, many pathophysiological mechanisms remain unclear. This review highlights their histopathology, focusing on malignant triton tumor.
- 17 December 2025
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (4) , 841-852
Pathological and Immunohistochemical Features of Malignant Peripheral Nerve Sheath Tumor With Heterologous Rhabdomy Oblastic Differentiation (Malignant Triton Tumor) in the Context of the Malignant Peripheral Nerve Sheath Tumor Spectrum
Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas arising from Schwann cells or neurofibromas, comprising ∼10% of soft tissue sarcomas. Found in 8% to 13% of neurofibromatosis type 1 patients, they typically show spindle cells expressing S100 and SOX10. Some display heterologous differentiation (bone, cartilage, vessels, or glands). When rhabdomyosarcomatous features are present, they are called malignant peripheral nerve heath tumor with heterologous rhabdomyoblastic differentiation (malignant triton tumors), which are more prone to recurrence, metastasis, and worse outcomes. Epithelial differentiation does not affect prognosis. Despite advances in understanding MPNST biology, many pathophysiological mechanisms remain unclear. This review highlights their histopathology, focusing on malignant triton tumor.
- 19 March 2025
- Published by Springer Nature in Current Oncology Reports
- Vol. 27 (4) , 472-482
History of Leukemia, Revisited
Purpose of the Review Provide a general historical overview of leukemia, emphasizing the early discoveries that led to its characterization. Recent Findings Leukemia recognition began in the late 19th century with the advent of the microscope. Leeuwenhoek and Swammerdam described erythrocytes, while Lieutaud first observed globuli albicantes, later identified as lymphocytes by Hewson. Early case studies by Velpeau, Donné, Bennett, Craigie, Virchow, and Fuller suggested that leukocytosis could occur without infection. Virchow coined the term “leukemia,” while Bennett proposed “leucocythemia.” Neumann identified the bone marrow as the source of blood cells and leukemia, coining the term “myelogenous leukemia,” and Ehrlich classified leukemia into myeloid and lymphoid types. In 1914, Boveri linked chromosomal abnormalities to cancer, and in 1960, Nowell and Hungerford discovered the Philadelphia chromosome. The use of mustard gas in WWI led to the development of chemotherapy drugs like chlorambucil and busulfan. The Human Genome Project further advanced leukemia diagnosis and treatment. Summary Leukemia, like many diseases, has evolved due to changes in causative factors such as viruses, bacteria, and genetic mutations, which have impacted its pathogenesis and treatment. It will undoubtedly continue to evolve, with new scientists working towards a cure for this devastating disease.
- 19 March 2025
- Published by Springer Nature in Current Oncology Reports
- Vol. 27 (4) , 472-482
History of Leukemia, Revisited
Purpose of the Review Provide a general historical overview of leukemia, emphasizing the early discoveries that led to its characterization. Recent Findings Leukemia recognition began in the late 19th century with the advent of the microscope. Leeuwenhoek and Swammerdam described erythrocytes, while Lieutaud first observed globuli albicantes, later identified as lymphocytes by Hewson. Early case studies by Velpeau, Donné, Bennett, Craigie, Virchow, and Fuller suggested that leukocytosis could occur without infection. Virchow coined the term “leukemia,” while Bennett proposed “leucocythemia.” Neumann identified the bone marrow as the source of blood cells and leukemia, coining the term “myelogenous leukemia,” and Ehrlich classified leukemia into myeloid and lymphoid types. In 1914, Boveri linked chromosomal abnormalities to cancer, and in 1960, Nowell and Hungerford discovered the Philadelphia chromosome. The use of mustard gas in WWI led to the development of chemotherapy drugs like chlorambucil and busulfan. The Human Genome Project further advanced leukemia diagnosis and treatment. Summary Leukemia, like many diseases, has evolved due to changes in causative factors such as viruses, bacteria, and genetic mutations, which have impacted its pathogenesis and treatment. It will undoubtedly continue to evolve, with new scientists working towards a cure for this devastating disease.
- Open Access
- 12 November 2024
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 160 (4) , 465-471
Los secretos de la cocina del Castillo de TuÓbingen: Friedrich Miescher y el descubrimiento de la nucleína, piedra angular del ADN
En 1869, Friedrich Miescher, nacido en Basilea, Suiza, descubrió una sustancia rica en fósforo, hasta entonces desconocida, en los núcleos de las células del pus. Al realizar su investigación en un laboratorio instalado en la cocina del castillo medieval de TuÌ?bingen, en Alemania, y bajo la dirección del profesor Felix Hoppe-Seyler, Miescher se centró principalmente en la composición de los núcleos celulares. Obtuvo material nuclear de las células del pus de vendajes quirúrgicos proporcionados por un hospital cercano. En 1869, Miescher describió una molécula nuclear completamente nueva que, a diferencia de las proteínas, contenía grandes cantidades de fósforo. Llamó a esta sustancia “nucleína”, con lo que marcó la primera descripción del ADN. Miescher falleció mucho antes de que Watson, Crick, Wilkins y Franklin anunciaran, en 1953, el papel preciso que desempeñaba el ADN en las células. A través de su descubrimiento, Miescher sentó las bases para todas las investigaciones posteriores sobre el ADN.
- 12 November 2024
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 160 (4) , 465-471
Open AccessLos secretos de la cocina del Castillo de TuÓbingen: Friedrich Miescher y el descubrimiento de la nucleína, piedra angular del ADN
En 1869, Friedrich Miescher, nacido en Basilea, Suiza, descubrió una sustancia rica en fósforo, hasta entonces desconocida, en los núcleos de las células del pus. Al realizar su investigación en un laboratorio instalado en la cocina del castillo medieval de TuÌ?bingen, en Alemania, y bajo la dirección del profesor Felix Hoppe-Seyler, Miescher se centró principalmente en la composición de los núcleos celulares. Obtuvo material nuclear de las células del pus de vendajes quirúrgicos proporcionados por un hospital cercano. En 1869, Miescher describió una molécula nuclear completamente nueva que, a diferencia de las proteínas, contenía grandes cantidades de fósforo. Llamó a esta sustancia “nucleína”, con lo que marcó la primera descripción del ADN. Miescher falleció mucho antes de que Watson, Crick, Wilkins y Franklin anunciaran, en 1953, el papel preciso que desempeñaba el ADN en las células. A través de su descubrimiento, Miescher sentó las bases para todas las investigaciones posteriores sobre el ADN.
- Open Access
- 17 November 2023
- Published by Instituto Mexicano del Seguro Social in Cirugía y Cirujanos (English Edition)
- Vol. 90 (1)
The latest anatomical discovery: the parathyroid glands or Glandulae parathyreoideae of Owen-Sandström-Gley
In 1852, Owen, a prominent British anatomist, described the parathyroid glands. While dissecting a rhinoceros, he noted a small compact yellow body, attached to the thyroid. Virchow and later Remak described the human parathyroids around 1960, but credit for the first complete description goes to the Sandström in 1980. More than a decade later Gley, showed that it was the removal of the parathyroids that accounted for the tetany that followed thyroidectomy. The association of parathyroid pathology and skeletal abnormalities was made in 1914 by Erdheim and Schlagenhaufer, and Mandl was the first surgeon to successfully treat a case of osteitis fibrosa by surgical removal of a parathyroid adenoma in 1925. The most extensive work on hyperparathyroidism was done in the 1930s by Albright from Boston, who described parathyroid hyperplasia, and differentiated between primary, secondary and tertiary hyperparathyroidism. Progresses in anatomy, physiology and surgery of the parathyroid glands, have contributed to various effective modalities of diagnosis and treatment.
- 17 November 2023
- Published by Instituto Mexicano del Seguro Social in Cirugía y Cirujanos (English Edition)
- Vol. 90 (1)
Open AccessThe latest anatomical discovery: the parathyroid glands or Glandulae parathyreoideae of Owen-Sandström-Gley
In 1852, Owen, a prominent British anatomist, described the parathyroid glands. While dissecting a rhinoceros, he noted a small compact yellow body, attached to the thyroid. Virchow and later Remak described the human parathyroids around 1960, but credit for the first complete description goes to the Sandström in 1980. More than a decade later Gley, showed that it was the removal of the parathyroids that accounted for the tetany that followed thyroidectomy. The association of parathyroid pathology and skeletal abnormalities was made in 1914 by Erdheim and Schlagenhaufer, and Mandl was the first surgeon to successfully treat a case of osteitis fibrosa by surgical removal of a parathyroid adenoma in 1925. The most extensive work on hyperparathyroidism was done in the 1930s by Albright from Boston, who described parathyroid hyperplasia, and differentiated between primary, secondary and tertiary hyperparathyroidism. Progresses in anatomy, physiology and surgery of the parathyroid glands, have contributed to various effective modalities of diagnosis and treatment.
- Open Access
Primary Cutaneous Anaplastic Large Cell Lymphoma—A Review of Clinical, Morphological, Immunohistochemical, and Molecular Features
Primary cutaneous anaplastic large cell lymphoma (ALCL) is the second most common cutaneous T-cell lymphoma after mycosis fungoides and belongs to the spectrum of cutaneous CD30+ T-cell lymphoproliferative disorders. Although primary cutaneous ALCL usually presents as a localized nodule or papule with or without ulceration, multifocal lesions may occur in up to 20% of cases. Histologically, primary cutaneous ALCL consists of a diffuse dermal infiltrate of medium to large anaplastic/pleomorphic cells with abundant amphophilic-to-eosinophilic cytoplasm, horseshoe-shaped nuclei, strong and diffuse expression of CD30, and with focal or no epidermotropism. The neoplastic infiltrate may show angiocentric distribution and may extend to the subcutis. Patients with localized or multifocal disease have a similar prognosis with a 10-year overall survival rate of 90%. Approximately 30% of primary cutaneous ALCLs harbor a DUSP22 (6p25.3) gene rearrangement that results in decreased expression of this dual-specific phosphatase, decreased STAT3 activation, and decreased activity of immune and autoimmune-mediated mechanisms regulated by T-cells.
Open AccessPrimary Cutaneous Anaplastic Large Cell Lymphoma—A Review of Clinical, Morphological, Immunohistochemical, and Molecular Features
Primary cutaneous anaplastic large cell lymphoma (ALCL) is the second most common cutaneous T-cell lymphoma after mycosis fungoides and belongs to the spectrum of cutaneous CD30+ T-cell lymphoproliferative disorders. Although primary cutaneous ALCL usually presents as a localized nodule or papule with or without ulceration, multifocal lesions may occur in up to 20% of cases. Histologically, primary cutaneous ALCL consists of a diffuse dermal infiltrate of medium to large anaplastic/pleomorphic cells with abundant amphophilic-to-eosinophilic cytoplasm, horseshoe-shaped nuclei, strong and diffuse expression of CD30, and with focal or no epidermotropism. The neoplastic infiltrate may show angiocentric distribution and may extend to the subcutis. Patients with localized or multifocal disease have a similar prognosis with a 10-year overall survival rate of 90%. Approximately 30% of primary cutaneous ALCLs harbor a DUSP22 (6p25.3) gene rearrangement that results in decreased expression of this dual-specific phosphatase, decreased STAT3 activation, and decreased activity of immune and autoimmune-mediated mechanisms regulated by T-cells.
- Open Access
- 9 December 2022
- Published by Instituto Mexicano del Seguro Social in Revista Hospital Juárez de México
- Vol. 89 (4) , 197-203
San Fiacro, patrono de las enfermedades anorrectales y algunos pacientes famosos aquejados con esta enfermedad
Cluso en los tiempos modernos, como parte de diferentes terapias para ciertas dolencias, se ha incluido la oración a los santos patrones para una posible intervención divina. San Fiacro fue un monje irlandés del siglo vii que se convirtió en el santo patrón de los que padecen enfermedades anorrectales. A lo largo de la historia, muchos son los que han implorado a San Fiacro para curaciones, han incluido diversos personajes como escritores famosos, presidentes y reyes. Pedirle protección a San Fiacro puede que no ayude, ¡pero no hará daño!
- 9 December 2022
- Published by Instituto Mexicano del Seguro Social in Revista Hospital Juárez de México
- Vol. 89 (4) , 197-203
Open AccessSan Fiacro, patrono de las enfermedades anorrectales y algunos pacientes famosos aquejados con esta enfermedad
Cluso en los tiempos modernos, como parte de diferentes terapias para ciertas dolencias, se ha incluido la oración a los santos patrones para una posible intervención divina. San Fiacro fue un monje irlandés del siglo vii que se convirtió en el santo patrón de los que padecen enfermedades anorrectales. A lo largo de la historia, muchos son los que han implorado a San Fiacro para curaciones, han incluido diversos personajes como escritores famosos, presidentes y reyes. Pedirle protección a San Fiacro puede que no ayude, ¡pero no hará daño!
- 18 August 2022
- Published by Elsevier in Revista Española de Patología
- Vol. 56 (3) , 201-205
Sarcoma sinovial pobremente diferenciado de pared del tórax con características rabdoides
- 18 August 2022
- Published by Elsevier in Revista Española de Patología
- Vol. 56 (3) , 201-205
Sarcoma sinovial pobremente diferenciado de pared del tórax con características rabdoides
- 3 December 2021
- Published by Springer Nature
- Vol. 2422, 17-31
Immunohistochemistry in Historical Perspective: Knowing the Past to Understand the Present
Immunohistochemistry is an extraordinary and extensively used technique whereby antibodies are used to detect antigens in cells within a tissue section. It has numerous applications in medicine, particularly in cancer diagnosis. It was Albert Hewett Coons, Hugh J Creech, Norman Jones, and Ernst Berliner who conceptualized and first implemented the procedure of immunofluorescence in 1941. They used fluorescein isothiocyanate (FITC)-labelled antibodies to localize pneumococcal antigens in infected tissues. Since then, with improvement and development of protein conjugation, enzyme labels have been introduced, such as peroxidase and alkaline phosphatase. The history of immunohistochemistry (IHC) combines physiology, immunology, biochemistry, and the work of various Nobel Prize laureates. From von Behring who was awarded de first Nobel Prize in 1901 for his work on serum therapy to the 1984 Nobel Prize for the discovery of monoclonal antibodies by Milstein, Kohler, and Jerne, IHC is a story of cooperation and collaboration which led to the development of this magnificent technique that is used daily in anatomical pathology laboratories worldwide.
- 3 December 2021
- Published by Springer Nature
- Vol. 2422, 17-31
Immunohistochemistry in Historical Perspective: Knowing the Past to Understand the Present
Immunohistochemistry is an extraordinary and extensively used technique whereby antibodies are used to detect antigens in cells within a tissue section. It has numerous applications in medicine, particularly in cancer diagnosis. It was Albert Hewett Coons, Hugh J Creech, Norman Jones, and Ernst Berliner who conceptualized and first implemented the procedure of immunofluorescence in 1941. They used fluorescein isothiocyanate (FITC)-labelled antibodies to localize pneumococcal antigens in infected tissues. Since then, with improvement and development of protein conjugation, enzyme labels have been introduced, such as peroxidase and alkaline phosphatase. The history of immunohistochemistry (IHC) combines physiology, immunology, biochemistry, and the work of various Nobel Prize laureates. From von Behring who was awarded de first Nobel Prize in 1901 for his work on serum therapy to the 1984 Nobel Prize for the discovery of monoclonal antibodies by Milstein, Kohler, and Jerne, IHC is a story of cooperation and collaboration which led to the development of this magnificent technique that is used daily in anatomical pathology laboratories worldwide.
- Open Access
ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas
Anaplastic large cell lymphoma (ALCL) is a subtype of CD30+ large T-cell lymphoma (TCL) that comprises ~2% of all adult non-Hodgkin lymphomas. Based on the presence/absence of the rearrangement and expression of anaplastic lymphoma kinase (ALK), ALCL is divided into ALK+ and ALK-, and both differ clinically and prognostically. This review focuses on the historical points, clinical features, histopathology, differential diagnosis, and relevant cytogenetic and molecular alterations of ALK- ALCL and its subtypes: systemic, primary cutaneous (pc-ALCL), and breast implant-associated (BIA-ALCL). Recent studies have identified recurrent genetic alterations in this TCL. In systemic ALK- ALCL, rearrangements in DUSP22 and TP63 are detected in 30% and 8% of cases, respectively, while the remaining cases are negative for these rearrangements. A similar distribution of these rearrangements is seen in pc-ALCL, whereas none have been detected in BIA-ALCL. Additionally, systemic ALK- ALCL—apart from DUSP22-rearranged cases—harbors JAK1 and/or STAT3 mutations that result in the activation of the JAK/STAT signaling pathway. The JAK1/3 and STAT3 mutations have also been identified in BIA-ALCL but not in pc-ALCL. Although the pathogenesis of these alterations is not fully understood, most of them have prognostic value and open the door to the use of potential targeted therapies for this subtype of TCL.
Open AccessALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas
Anaplastic large cell lymphoma (ALCL) is a subtype of CD30+ large T-cell lymphoma (TCL) that comprises ~2% of all adult non-Hodgkin lymphomas. Based on the presence/absence of the rearrangement and expression of anaplastic lymphoma kinase (ALK), ALCL is divided into ALK+ and ALK-, and both differ clinically and prognostically. This review focuses on the historical points, clinical features, histopathology, differential diagnosis, and relevant cytogenetic and molecular alterations of ALK- ALCL and its subtypes: systemic, primary cutaneous (pc-ALCL), and breast implant-associated (BIA-ALCL). Recent studies have identified recurrent genetic alterations in this TCL. In systemic ALK- ALCL, rearrangements in DUSP22 and TP63 are detected in 30% and 8% of cases, respectively, while the remaining cases are negative for these rearrangements. A similar distribution of these rearrangements is seen in pc-ALCL, whereas none have been detected in BIA-ALCL. Additionally, systemic ALK- ALCL—apart from DUSP22-rearranged cases—harbors JAK1 and/or STAT3 mutations that result in the activation of the JAK/STAT signaling pathway. The JAK1/3 and STAT3 mutations have also been identified in BIA-ALCL but not in pc-ALCL. Although the pathogenesis of these alterations is not fully understood, most of them have prognostic value and open the door to the use of potential targeted therapies for this subtype of TCL.
- 1 November 2020
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 156 (6) , 595-603
Carl von Rokitansky, the Linne of pathological anatomy
- 1 November 2020
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 156 (6) , 595-603
Carl von Rokitansky, the Linne of pathological anatomy